Executives On The Move
Recent moves in the industry include C-suite changes at Coya Therapeutics, Kancera and Verrica Pharmaceuticals, which acquires chief financial officer from Aceragen.
Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.
Recent moves in the industry include changes at the top at enGene Holdings, which also acquires chief technology officer from Albireo Pharma.
Recent moves in the industry include changes at the top at Defence Therapeutics, Trevena and Neurocrine Biosciences, plus Alpha Cognition gets a new chief Financial officer.
Recent moves in the industry include C-suite changes at Cybin, Biomarin and Nuvation Bio, plus Novita Pharmaceuticals gets a new chief executive officer.
Recent changes in the industry include changes at the top at Prothena and 180 Life Sciences, plus Cantargia acquires chief business officer from Ultimovacs.
Other recent moves in the industry include changes at the top at Adocia, CSL and Entrada Therapeutics.
Recent moves in the industry include C-suite changes at Ovid Therapeutics and Genor Biopharma, plus Structure Therapeutics acquires chief development officer from Reneo Pharmaceuticals and BioDuro-Sundia acquires chief executive officer from Crown Bioscience.
Recent moves in the industry include changes at the top at LakeShore Biopharma, Atara Biotherapeutics and Defence Therapeutics, plus Transgene gets new chief medical and scientific officers.
Recent moves in the industry include C-suite shuffle at Quantum Biopharma, Affimed and GH Research, plus Belite Bio and Dyne Therapeutics get new chief medical officers.
Kamil Hamied, son of Cipla’s outgoing vice-chair M K Hamied, is set to re-join the company as non-executive director, following his "entrepreneurial journey." Does it signal a shift in the promoter group’s immediate considerations amid past stake sale speculation or mark routine top-level executive changes?
Recent moves in the industry include new hires at Duality Biotherapeutics, Achieve Life Sciences and Clarity Pharmaceuticals.
In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.
Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.
Recent moves in the industry include changes at the top for Xilio Therapeutics, Zentalis Pharmaceuticals, Beam Therapeutics and Cipher Pharmaceuticals, plus Ardelyx gets a new chief commercial officer.
Recent moves in the industry include C-suite shuffles at Valeo Pharma, Xeris Biopharma, ALX Oncology and MEI Pharma, plus BeiGene and Phio Pharmaceuticals get new chief financial officers.
Recent moves in the industry include C-suite shuffle at Nkarta, plus I-Mab gets a new CEO.
Recent moves in the industry include C-suite shuffles at Pulmatrix, Intellia Therapeutics and BridgeBio, while Akeso got a new chief financial officer from Cellectis.
Recent moves in the industry include C-suite shuffles at AbbVie, Abivax and Ikena Oncology, plus I-Mab.
In this week's podcast edition of Five Must-Know Things: Q1’s top 10 drugs; Pfizer’s R&D leadership succession; Lilly bolsters IBD pipeline; first half deal volume up but value down; and EU firms’ China sentiment plummets.